Neuraxis, INC (NRXS): Submission of Matters to a Vote of Security Holders
Neuraxis, INC (NRXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (As Amended As of June 11, 2026) Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS 1 ARTICLE III EFFECTIVE DATE OF PLAN 6 ARTICLE IV ADMINISTRATION 6 Section 4.1 Ad
How this was made
The 30-second read
Why it matters
The attached plan governs equity awards (options, RSUs, restricted stock, SARs, etc.) and can influence future dilution and compensation expense, but the provided excerpt does not state the vote results or any quantified share-authorization change.
Market read
Company-specific SEC filing tied to a shareholder vote on an amended equity incentive plan; potential dilution/compensation implications, but no explicit financial or strategic catalyst in the excerpt.
What to watch
Traders should check the full 8-K for the specific proposal(s) and any changes to authorized shares, option limits, or voting outcomes—those details drive dilution sensitivity more than the plan text.
Background
The SEC 8-K Item 5.07 indicates matters were submitted to a vote of security holders; the exhibit includes the company’s 2022 Omnibus Securities and Incentive Plan amended as of June 11, 2026.
Ticker impact
Neuraxis filed an 8-K disclosing the submission of matters to a vote of security holders and attached its amended 2022 omnibus equity incentive plan (as of June 11, 2026).
Near-term impact likely limited unless the vote includes material share-authorization changes; otherwise treat as low-volatility governance noise.
The filing is primary-source (SEC 8-K) and company-specific, but the excerpt is largely plan boilerplate without explicit approval outcomes or quantified share-cap changes.
Market effects
Minimal; equity-plan amendments are common across biotech/small-cap issuers and don’t signal sector-wide regulatory or clinical changes by themselves.
None indicated.
None indicated.
Counterpoint
If the vote includes meaningful increases to the share pool or option/SAR limits, the market may reprice dilution risk even without clinical/financial catalysts.
Key entities
- issuerNeuraxis, Inc.
Company filing the 8-K and providing the amended 2022 omnibus securities and incentive plan for a security-holder vote.
- corporate_actionSecurity holders vote
Shareholder vote process referenced by Item 5.07, which may include approval of the amended equity incentive plan.
